SILVER SPRING, Md., Aug. 1, 2011 /PRNewswire-USNewswire/ --Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of Aug. 1, 2011.
(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)
FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.
Meetings, Workshops and Congressional Testimony:
Tuesday, 8/2 Final day of the FDA Humanitarian Use Device Workshop, an opportunity to develop applications for devices intended to treat or diagnosis a rare disease or condition. 8 a.m., University of Minnesota-Twin Cities Campus, Moos Tower, 515 Delaware Street SE, Minneapolis.
Press Office Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Tuesday, 8/2 Start of a three-day FDA Orphan Drug Workshop, to develop applications for orphan status designation for drugs to treat rare diseases. 8 a.m., University of Minnesota-Twin Cities Campus, Moos Tower, 515 Delaware Street S.E., Minneapolis.
Press Office Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Tuesday, 8/2 The FDA Blood Products Committee discusses a study on the incidence of Trypanosoma cruzi infection in blood donors and implications for selective testing of blood donors. 1:30 p.m., Hilton Washington D.C./North, 620 Perry Pkwy., Gaithersburg, Md.
Press Office Contact: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov
Wednesday, 8/3 The FDA Blood Products Committee discusses measures to preserve the blood supply during a severe emergency beginning at 8 a.m. In the afternoon, the committee hears briefings on several meetings, including the Health and Human Services Advisory Committee on Blood Safety and Availability, a public workshop on risk mitigation strategies to address procoagulant activity in immune globulin products, and the Transmissible Spongiform Encephalopathies Advisory Committee. Hilton Washington D.C./North, 620 Perry Pkwy., Gaithersburg, Md.
Press Office Contact: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov
FDA Office of Public Affairs Contact Information:
Call or email FDA Office of Public Affairs, 301-796-4540, fdaopa@fda.hhs.gov
List of FDA press officers and beats
More Resources:
FDA News and Events
FDA Photos (Flickr)
Consumer Health Information
SOURCE U.S. Food and Drug Administration
